Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLN-418
- Development stage
- Discontinued
- Lead developer
- Harbour BioMed
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CLN-418 is a clinical-stage bispecific monoclonal antibody that targets both B7H4 (a tumor-associated antigen highly expressed in multiple solid tumors) and 4-1BB (Tumor necrosis factor receptor superfamily member 9, a costimulatory molecule important for T and NK cell activation). The drug is designed to conditionally activate 4-1BB signaling only in the presence of B7H4-expressing tumor cells, thereby promoting targeted T cell activation and anti-tumor immune responses while minimizing off-target toxicity. This mechanism aims to improve safety compared to non-selective 4-1BB agonists. CLN-418 is being developed by Cullinan Oncology, with rights licensed from Harbour BioMed, and is currently being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors[1][3][5][6].
- Other names
- anti-B7-H4/anti-4-1BB bispecific antibody CLN-418
02
Targets
VTCN1 (V-set domain containing T cell activation inhibitor 1)TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on CLN-418.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLN-418.